SIREN : 350019261
HUVEPHARMA SA is a French company founded 37 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in SEGRE-EN-ANJOU BLEU (49500), this company of category PME shows in 2024 a revenue of 46.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45 972 280 € | 39 337 153 € | 39 313 921 € | 40 477 776 € | 39 364 360 € | 36 024 200 € | 25 624 406 € | 12 245 025 € | 26 386 362 € | 27 272 160 € |
| Net income | 2 358 947 € | 845 147 € | 856 944 € | 1 812 450 € | 1 942 163 € | 1 153 976 € | 505 456 € | -12 612 € | 130 022 € | -737 479 € |
| EBITDA | 4 534 802 € | 1 824 695 € | 1 940 833 € | 3 823 050 € | 3 720 014 € | 2 540 794 € | 1 071 427 € | -83 064 € | 348 778 € | 710 745 € |
| Net margin | 5.1% | 2.1% | 2.2% | 4.5% | 4.9% | 3.2% | 2.0% | -0.1% | 0.5% | -2.7% |
In 2024, HUVEPHARMA SA achieves revenue of 46.0 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +6.7%. Vs 2023, growth of +17% (39.3 M€ -> 46.0 M€). After deducting consumption (28.0 M€), gross margin stands at 18.0 M€, i.e. a rate of 39%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 4.5 M€, representing 9.9% of revenue. Positive scissor effect: EBITDA margin improves by +5.2 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.4 M€, i.e. 5.1% of revenue. This profit can be retained or distributed to shareholders.
45 972 280 €
18 003 475 €
4 534 802 €
3 572 800 €
2 358 947 €
9.9%
The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 63%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 7.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
1.121%
62.81%
7.03%
0.0
29.4%
In 2024, the debt ratio of HUVEPHARMA SA (1.12) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of HUVEPHARMA SA (62.8%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of HUVEPHARMA SA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 213.50. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.0x. Coverage is limited: any activity downturn would jeopardize interest payments.
213.497
1.002
In 2024, the liquidity ratio of HUVEPHARMA SA (213.50) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of HUVEPHARMA SA (1.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 53 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 72 days. Favorable situation: supplier credit is longer than customer credit by 19 days. Inventory turnover is 56 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 130 days of revenue, i.e. 16.6 M€ to permanently finance. Over 2016-2024, WCR increased by +79%, requiring additional financing.
16 614 842 €
53 j
72 j
56 j
130 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 470 655€ to 1 446 610€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare HUVEPHARMA SA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of HUVEPHARMA SA in 2024 is 46.0 M€.
Yes, HUVEPHARMA SA generated a net profit of 2.4 M€ in 2024.
The headquarters of HUVEPHARMA SA is located in SEGRE-EN-ANJOU BLEU (49500), in the department Maine-et-Loire.
The tax return of HUVEPHARMA SA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
HUVEPHARMA SA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.